1. INTRODUCTION {#S5}
===============

Sickle cell disease (SCD) is caused by the presence of an abnormal hemoglobin S (HbS) which results from a single base substitution in the beta-globin gene of hemoglobin. Polymerization of deoxygenated-HbS leads to "sickling" of red blood cells, resulting in chronic hemolytic anemia and recurrent episodes of acute vaso-occlusive pain. All patients have progressive end-organ damage and a reduced life expectancy. SCD is a multisystem disorder with multiple organ damage associated with recurring inflammation caused by tissue ischemia, reperfusion injury, and vascular damage.^[@R1]--[@R5]^ Several markers of inflammation are elevated in SCD, including total white cell count, secretory phospholipase A2, interleukins, prostaglandin-E2, and Tumor Necrosis Factor-α.^[@R6]--[@R10]^ Acute phase reactants, proteins which rise or fall as a reaction to proinflammatory cytokines, include C-reactive protein (CRP) and ferritin. Platelets and haptoglobin are also elevated during inflammation.^[@R11]^ However, the inherent variability of the plasma levels of these proteins challenges the ability to identify a biomarker with sufficient sensitivity and specificity for detecting acute crises. For instance, raised CRP levels in steady state are correlated with increased frequency of pain crisis and elevated levels are found during acute pain crises and acute chest syndrome.^[@R8],[@R9],[@R12]^ However, studies have found significant interindividual variability, a short half-life and a wide reference range for this marker.^[@R13]^ As inflammation is a key biological event accompanying acute vaso-occlusive crisis, a specific biomarker of inflammation would potentially be useful to determine disease activity in SCD.

GlycA shows promise as a biomarker of inflammation and disease severity in chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus (SLE).^[@R14]--[@R17]^ GlycA is a composite signal derived from (^1^H) nuclear magnetic resonance (NMR) spectra of the N-acetyl methyl group protons of the carbohydrate side chains of mainly four positive acute phase proteins: α1-acid glycoprotein, haptoglobin, α1-antitrypsin, and α1-antichymotrypsin, and one negative acute phase protein, transferrin.^[@R13],[@R18]--[@R21]^ Positive acute phase proteins increase, while negative acute phase proteins decrease, in response to inflammation. GlycA has relatively low interindividual variability compared with CRP and appears to have prognostic value as an indicator of treatment response and disease activity.^[@R19]^ We evaluated the plasma GlycA levels in a cross-sectional sample of patients with SCD and specifically tested its levels in patients experiencing an acute painful vaso-occlusive crisis (VOC).

2. MATERIALS AND METHODS {#S6}
========================

2.1. Study definitions {#S7}
----------------------

An "acute pain vaso-occlusive crisis" was defined as a visit to the NIH Clinical Center for acute pain without evidence of an alternative etiology, for which the patient requires hospitalization and treatment with parenteral narcotic medication. "Steady state" was defined as the period when patients were in their usual state of health and excluded the 8-week time period prior to or after an acute pain crisis. Patients with SCD included HbSS, HbSBeta^0^ thalassemia, and HbSC genotypes from Groups 1 and 2. For analysis purposes, HbSS and HbSBeta^0^ thalassemia were considered as one phenotypic group of sickle cell anemia (SCA) due to similarity of clinical disease severity.

2.2. Study participants {#S8}
-----------------------

Group 1 consisted of a cross-sectional sample of 488 patients with SCD (392 HbSS; 15 HbSBeta^0^ thalassemia; 81 HbSC) not experiencing an acute pain crisis and who reported themselves to be in their usual state of health "steady state." These patients were prospectively enrolled from 2001 to 2015 (NCT00011648). Twenty-three patients (21 HbSBeta^+^ thalassemia; 1 HbSD; 1 HbSO Arab) and one sample with an undetectable GlycA level were excluded from analysis. Group 1 additionally included 52 healthy African Americans enrolled as healthy controls.

A second group (Group 2) included paired samples obtained from patients with SCD in steady state and again during an acute pain crisis (NCT03049475). For analysis, this consisted of paired samples from 12 HbSS patients. Steady state samples obtained from Groups 1 (n = 488) and 2 (n = 12) were analyzed as a SCD cross-sectional group (n = 500; [Figure 1](#F1){ref-type="fig"}). Both studies were approved by the Institutional Review Board of the National Institutes of Health and written informed consent was obtained from all participants.

2.3. Sample processing {#S9}
----------------------

Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood samples were collected and centrifuged for 10 minutes at 1200 *g*. The resulting supernatant plasma was removed by pipetting, transferred to Sarstedt Micro tubes, snap-frozen in liquid nitrogen, and stored at −80°C until use.

Hematological and biochemical parameters were obtained from routine hospital laboratory measurements at steady state and during acute pain crisis.

2.4. GlycA measurements {#S10}
-----------------------

Aliquots of frozen plasma (500 μL) were thawed at 4°C for 24 hours. Subsequently, 450 μL was transferred to a cell-strainer capped Falcon™ Round-Bottom Polypropylene (Thermo Fisher Scientific, Hampton, NH, USA) test tubes on the day of analysis. Using previously described methodology, plasma GlycA was quantified in these samples with a 400 MHz proton (^1^H) NMR spectrometer (Vantera^®^ Clinical Analyzer, LipoScience Inc., NC, USA).^[@R22]--[@R24]^

2.5. Statistical analysis {#S11}
-------------------------

Variables with a Gaussian distribution (*t* test or one-way analysis of variance) were aggregated into means with standard deviations (SD). Intraindividual paired samples were compared using the paired *t* test. Correlations between GlycA and markers of inflammation and hemolysis were assessed using the Pearson test. The conventional threshold of \<0.05 was used for statements about statistical significance. All statistical analysis was performed using GraphPad Prism version 7.00 for Mac (GraphPad Software, La Jolla, CA, USA).

3. RESULTS {#S12}
==========

3.1. Baseline characteristics {#S13}
-----------------------------

Five hundred patients with SCD from Group 1 and Group 2 were included in our study as detailed in [Figure 1](#F1){ref-type="fig"}. The mean age was 34 ± 12.7 years and 236 (47%) were female. Two hundred and two of the 500 (40%) of these patients were receiving hydroxyurea. During steady state, the mean hemoglobin and white cell count were 91 ± 1.9 g/L and 10.6 ± 4.2 × 10^9^/L, respectively. During acute pain crisis, the mean hemoglobin and mean white cell count were 90 ± 1.1 g/L and 9.8 ± 6.0 × 10^9^/L, respectively. Ongoing hemolysis was reflected by elevated steady state levels of serum lactate dehydrogenase (LDH) mean 6.4 ± 19.4 μkat/L and an elevated absolute reticulocyte count, 255.7 ± 143.5 cells/mm^3^. Evidence for the presence of inflammation was supported by an elevated CRP (48.6 ± 9.7 μg/L; [Table 1](#T1){ref-type="table"}). Patients sampled during an acute vaso-occlusive crisis demonstrated similar LDH values (6.4 ± 22.5 μkat/L) and absolute reticulocyte count (226.3 ± 107.5 cells/mm^3^) but had slightly higher CRP values (69.5 ± 9.0 nm/L; [Table 2](#T2){ref-type="table"}).

3.2. Plasma GlycA levels in SCD {#S14}
-------------------------------

The mean plasma GlycA level was lower in SCD steady state patients from Groups 1 and 2 compared with healthy control patients (324.6 ± 70.4 μmol/L vs 386.3 ± 74.6 μmol/L; *P* \< 0.0001). When analyzed by genotype, both the SCA patients from Groups 1 and 2 and the HbSC patients from Group 1 had lower plasma GlycA levels compared with healthy controls (321.4 ± 70.0 μmol/L vs 386.3 ± 74.6 μmol/L; *P* \< 0.0001 and 341.4 ± 70.0 μmol/L vs 386.3 ± 74.6 μmol/L; *P* = 0.001, respectively; [Figure 2](#F2){ref-type="fig"}). Patients with the clinically more severe SCA genotype were found to have decreased plasma GlycA levels compared with the less clinically severe HbSC genotype (321.4 ± 70.0 μmol/L vs 341.4 ± 70.0 μmol/L; *P* = 0.0905), but the results did not reach statistical significance.

The plasma GlycA level was further lowered during an acute pain crisis when compared with the steady state GlycA level for paired HbSS patients from Group 2 (300.5 ± 36.3 μmol/L vs 314.2 ± 34.8 μmol/L; *P* = 0.020). Similar findings were shown when the plasma GlycA level of HbSS patients during an acute pain crisis (Group 2) was compared with SCA patients (Group 1 and Group 2) at steady state (300.5 ± 36.3 μmol/L vs 321.4 ± 70.0 μmol/L; *P =* 0.305; [Table 2](#T2){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}).

3.3. Correlation of plasma GlycA levels with hemolysis markers {#S15}
--------------------------------------------------------------

There was a negative correlation between plasma GlycA in SCD steady state and LDH (*P =* 0.0089). Correlations with other hemolysis markers did not reveal significant findings.

4. DISCUSSION {#S16}
=============

Several recent studies of diseases involving chronic vascular inflammation, namely psoriasis^[@R14]^ and SLE,^[@R17]^ have found that plasma GlycA levels are higher compared with healthy controls. As SCD is a known proinflammatory condition, we hypothesized that the plasma GlycA levels would also be similarly be elevated among SCD patients compared with healthy controls.^[@R1],[@R11],[@R13],[@R15],[@R25]^ We also hypothesized that the plasma GlycA level would be further elevated during VOCs when compared with its level during the steady state, reflecting the increased inflammation accompanying acute pain in SCD. On the contrary, we found (a) reduced levels of plasma GlycA in a cross section of patients with HbSS/HbSβ^0^ thalassemia and HbSC disease compared with healthy control patients; (b) lower plasma GlycA levels in the HbSS/HbSβ^0^ thalassemia genotypes compared with HbSC; (c) further reduction in plasma GlycA levels in patients with SCD experiencing an acute painful crisis compared to GlycA levels in the same patient and in the SCD pooled cohort of patients in steady state; and (d) a significant negative correlation of GlycA with LDH, a plasma marker of hemolysis.

Ongoing inflammation as a result of recurrent painful vaso-occlusive crisis with reperfusion injury is thought to mediate in part the vascular pathobiology of SCD.^[@R1],[@R26]--[@R28]^ While elevated CRP levels provided biochemical evidence for inflammation in our patients with SCD, the GlycA values obtained were paradoxically lower than healthy controls and also lower than reported in other inflammatory diseases.^[@R8],[@R9],[@R11],[@R13]^ For example, studies have shown the plasma GlycA level in rheumatoid arthritis and SLE was 353.8 ± 65.2 μmol/L and 408.0 ± 75.4 μmol/L, respectively, compared with 324.6 ± 70.4 μmol/L in our patients with SCD.^[@R14],[@R16]^ We attributed these seemingly contradictory results to hemolysis observed in the patients with SCD, which is not observed in the other two diseases.^[@R29]^ It would be interesting to compare the GlycA levels in other diseases involving hemolytic anemia where haptoglobin is depleted and there is a less pronounced inflammatory response, such as pyruvate kinase deficiency or hereditary spherocytosis.

The GlycA signal is a compilation of five acute phase proteins, four of which are elevated during inflammation, one of which is haptoglobin.^[@R13],[@R18]^ However, haptoglobin is a scavenger of free hemoglobin and becomes rapidly depleted during intravascular hemolysis. The negative correlation between the plasma GlycA level and LDH, an indirect marker of hemolysis, supports this hypothesis.^[@R12],[@R30]--[@R33]^ Our data, therefore, suggest that hemolysis in SCD nullifies GlycA as a valid biomarker of inflammation in SCD. Measuring GlycA in patients with SCD in their steady state also appears to be futile as ongoing chronic hemolysis renders haptoglobin immeasurable. The strengths of this study are the quantification of a novel plasma biomarker of inflammation in a large cohort of patients with SCD and the inclusion of paired samples obtained during steady state and an acute painful crisis. The Vantera^®^ Clinical Analyzer is an automated NMR spectrometer with an inbuilt deconvolution algorithm designed to ease clinical utility. This design unfortunately limited our ability to interrogate the individual components of the GlycA signal to further investigate the effect of hemolysis on the GlycA measurement.^[@R22]^

5. CONCLUSION {#S17}
=============

GlycA a composite signal derived from five acute phase reactants is not a useful biomarker of inflammation in SCD. Plasma GlycA measurements in patients with SCD appear to be confounded by hemolysis. Further studies are warranted to identify a more specific biomarker of inflammation for this complex disorder.
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![GlycA levels in plasma (μmol/L) of the 12 paired HbSS patients who provided samples during steady state and acute pain crisis (Group 2). The steady state and crisis samples are each a single value. Mean plasma GlycA level in steady state was 314.2 ± 34.8 μmol/L and during an acute pain crisis was 300.5 ± 36.3 μmol/L (*P* = 0.020)](nihms-1016401-f0003){#F3}

###### 

Descriptive data for Group 1 study cohort and healthy controls. Steady state values are given for hematological and biochemical parameters. Data were summarized by the mean ± SD

                              SCD patients in steady state   Controls       
  --------------------------- ------------------------------ -------------- ---------------
  N                           392                            81             52
  Male:female                 202: 205                       36: 45         22:30
  Age, years (mean, SD)        33.1 ± 12.1                    38.3 ± 14.4    36.4 ± 11.7
  WBC (×10^9^/L)               11.3 ± 4.2                      7.7 ± 2.4      5.9 ± 1.5
  Hemoglobin (g/L)              86 ± 1.6                      115 ± 1.5      13.1 ± 1.6
  Hematocrit (fraction)        0.25 ± 4.6                     0.33 ± 4.4     0.29 ± 4.1
  Absolute retic (cells/uL)   280.4 ± 142.7                  127.8 ± 49.7    59.2 ± 27.6
  CRP (nm/L)                   53.3 ± 9.9                     31.4 ± 9.0     22.9 ± 3.1
  ALT (U/L)                    36.2 ± 49.3                    24.6 ± 13.3    27.3 ± 14.1
  AST (U/L)                    50.1 ± 87.2                    26.7 ± 17.2    20.1 ± 8.1
  Bilirubin, total (μmol/L)    54.7 ± 2.3                     27.4 ± 0.9     10.3 ± 0.3
  LDH (μkat/L)                  6.9 ± 19.9                     4.0 ± 7.4      2.9 ± 4.5
  Haptoglobin (mg/L)          104.0 ± 15.8                   230.0 ± 40.8   1132.0 ± 65.2

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, c-reactive protein; LDH, lactate dehydrogenase; SCD, HbSS + HbSβ^0^ thalassemia + HbSC genotypes; WBC,white blood cell count.

###### 

Descriptive data for Group 2 study cohort of paired HbSS patient samples in steady state and during an acute pain crisis. Data were summarized by the mean ± SD

  ------------------------------------------------------------------------------------------
                              Steady state (HbSS;\   Acute pain crisis (HbSS;\   *P*-value
                              n = 12)                n = 12)                     
  --------------------------- ---------------------- --------------------------- -----------
  Age-yrs. 40.1 ± 10.5 y                                                         

  Female n = 8 (66.7%)                                                           

  Male n = 4 (33.3%)                                                             

  WBC (×10^9^/L)              7.4 ± 3.4              9.8 ± 6.0                   0.211

  Hemoglobin (g/L)            97 ± 1.0               90 ± 1.1                    0.002

  Hematocrit (fraction)       0.27 ± 2.4             0.25 ± 2.7                  0.003

  Absolute retic (cells/μL)   252.8 ± 160            226.3 ± 107.5               0.912

  CRP (nm/L)                  30.5 ± 2.4             69.5 ± 9.0                  0.211

  ALT (U/L)                   25.3 ± 8.67            31.3 ± 23.8                 0.420

  AST (U/L)                   34.8 ± 14.4            52.3 ± 45.5                 0.342

  Bilirubin, total (μmol/L)   35.9 ± 1.3             39.3 ± 1.3                  0.977

  LDH (μkat/L)                2.9 ± 16.4             6.4 ± 22.6                  0.034
  ------------------------------------------------------------------------------------------

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell count.
